Trials
4 active
6 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The dose levels will be escalated following a 3+3 dose escalation scheme.”In the company’s words, NCT07364422 on ClinicalTrials.gov
- Main trialPhase 2
- “This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients”In the company’s words, NCT07370818 on ClinicalTrials.gov
Other drugs for Ovarian Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab soravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
Coming up2
- 31 Dec 2029Phase 2 trial completes · ClinicalTrials.gov
- Apr 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 31 Dec 2029 | To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer | |
| Phase 1/2Not yet recruiting | 28 Feb 2026 | To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer | |
| Phase 1/2Recruiting | Apr 2030 | Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer | |
| Phase 1Not yet recruiting | Jul 2026 | Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants | |
| Phase 2Unknown | Nov 2024 | A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor | |
| Phase 1Completed | 14 Dec 2021 | A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026